The Competition and Consumer Commission of Singapore (CCCS) has granted conditional approval for the completed merger of two private clinical laboratories, after accepting four-year commitments from Pathology Asia Holdings (PAH).
PAH, a unit of private equity giant TPG Capital Asia, integrated the businesses of the two labs – Innovative Diagnostics and Quest Laboratories – after acquiring them last year.
Both labs provide in-vitro diagnostic (IVD) tests in Singapore, which can be used to detect diseases or other conditions and monitor a person’s health.
Pre-merger, Innovative, and Quest had been the closest competitors to each other, as they were the top two suppliers of IVD tests among private clinical labs in Singapore, CCCS announced on Monday, October 21.
Full Content: Business Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
